Company intelligence / Profile preview

Archer Pharmaceuticals

Sarasota, Florida, United Statesarcherpharmaceuticals.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Archer Pharmaceuticals specializes in drug discovery and development targeting Alzheimer's disease. Its lead compound, ARC029 (nilvadipine), was evaluated through a large European Phase III trial but did not demonstrate efficacy over placebo. The company continues to develop next-generation compounds such as ARC031 with improved safety profiles. Their approach centers on repurposing known small molecules with mechanistic rationale supported by preclinical data.

Therapeutic areas: Neurology
Modalities: Small moleculesRepurposed drugs (notably calcium channel blockers)
Industry: Biotech

Drug pipeline

2 assets

nilvadipine

1 more asset in the full pipeline.

Partnerships

Participated in the NILVAD consortium—a major European academic-industry collaboration for the nilvadipine Phase III trial.

Beyond the preview

Go deeper on Archer Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Archer Pharmaceuticals.